Antares pharma inc.

EWING, NJ, March 3, 2022 – Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net ...May 24, 2022 ... As of May 24, 2022, Antares common stock will cease to be traded on the NASDAQ Global Select Stock Market. BofA Securities, Inc. and Wells Fargo ...Abstract. Medi-Ject Corporation (now Antares Pharma, Inc.) has been providing delivery devices for the needle-free administration of insulin for over 25 years. This study was one of the final steps in the development and premarket evaluation of Medi-Ject's newest needle-free system, the Medi-Jector Vision. This study was conducted to evaluate ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. Jun 28, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...

Apr 14, 2022 · Credit: Arek Socha from Pixabay. Halozyme Therapeutics has signed a definitive agreement for the acquisition of all of the outstanding shares of Antares Pharma in a deal valued at nearly $960m or $5.60 for each share, in cash. A speciality pharmaceutical firm, Antares focuses on developing pharmaceutical products and technologies to address ... Reinventing the patient experience. The patient is at the forefront of everything we do at Halozyme. With our disruptive drug delivery technologies and robust commercial portfolio, we are committed to reinventing the patient experience by easing the burden of treatment and improving patient outcomes. 2015-2023. Halozyme, Inc.

Antares Pharma announces FDA approval of Tlando™, an oral treatment for testosterone replacement therapy. News release. Antares Pharma Inc. Accessed March 29, 2022.ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) _____ Delaware: 1-32302: 41-1350192 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South, Suite 300, Ewing, ...Antares Pharma, Inc., a leader in self-injection drug delivery technology, announced the latest advancement in its proprietary line of VIBEX(TM) auto-injectors. Antares’ new VIBEX QS auto-injector platform offers a dose capacity of 1 mL and greater in a compact design. VIBEX QS achieves this advance by incorporating a novel triggering ...On April 12, 2022, Halozyme Therapeutics, Inc. (the “Buyer”, “Halozyme”, “Parent”, “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Antares Pharma, Inc., a Delaware corporation (the “Seller” or “Antares”), and Atlas Merger Sub, Inc. (“Merger Sub” or the “Acquirer”), a Delaware corporation and wholly owned …SAN DIEGO, May 24, 2022 — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced the successful completion of its acquisition of Antares Pharma, Inc. (“Antares”). The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, May ...

Antares Pharma Inc (NASDAQ:ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ:HALO) for $5.60 per share in cash, valuing ...

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

Aug 5, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.Reinventing the patient experience. The patient is at the forefront of everything we do at Halozyme. With our disruptive drug delivery technologies and robust commercial portfolio, we are committed to reinventing the patient experience by easing the burden of treatment and improving patient outcomes. 2015-2023. Halozyme, Inc. 27 Oct, 2021, 11:30 ET. NEW YORK, Oct. 27, 2021 /PRNewswire/ -- The testosterone replacement therapy market size is expected to increase by USD 113.54 million from 2019 to 2024, registering a CAGR ...Antares Pharma, Inc. (Antares or 'the company') is a drug device company that develops and markets self-injection pharmaceutical products and technologies. The company develops these products with its partners and is designed to provide functional and commercial advantages, such as reduced side effects, improved safety and efficacy and enhanced ...Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …

On behalf of Antares Pharma, Inc. (the “Company”), following are the Company’s responses to the Staff’s comment on the above-captioned filing conveyed in the Staff’s comment letter dated June 6, 2005 (the “Comment Letter”). The Company’s responses to the Comment Letter were filed electronically via EDGAR, with three (3) additional …Dec 15, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... 13. 4. 2022 ... Antares Pharma to be acquired by Halozyme in $960M deal ... Robert Apple, CEO of Antares Pharma. ... Antares, which was originally founded in Exton, ...Description. Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral …Get directions. Antares Pharma Inc. | 5,022 followers on LinkedIn. Making Medicines Feel Better | About Antares Antares Pharma is a specialty pharmaceutical company that combines drug...Becton, Dickinson and Company, Sanofi, Pfizer, Inc, Mylan N.V., Novartis AG, Bayer AG, Janssen Global Services, LLC, Antares Pharma, Inc., Amgen Inc, Eli Lilly and Company, Teva Pharmaceutical, Merck KgaA, GlaxoSmithKline plc, Ypsomed, SHL Medical, Gerresheimer AG, Midas Pharma GmbH, Aptar Pharma, Solteam Medical, …Antares Pharma, Inc.: Otrexup is a folate analog metabolic inhibitor indicated for the: Management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis...

Senior Director of Managed Care, Trade Relations & Government Pricing at Antares Pharma Inc. Antares Pharma Inc. Oct 2018 - Present 4 years 11 months. Director of Managed Care & Market Access ...

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Pipeline :: Antares Pharma. Halozyme has completed its acquistion of Antares Pharma, creating a leading drug delivery business. View details here. Invisible Fence Inc. is a leading provider of innovative pet containment and lifestyle solutions. With over 40 years of experience, Invisible Fence Inc. has developed products that are designed to keep pets safe and secure in their own yard...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ...SAN DIEGO, May 24, 2022 — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced the successful completion of its acquisition of Antares Pharma, Inc. (“Antares”). The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, May ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...On April 12, 2022, Halozyme Therapeutics, Inc. (the “Buyer”, “Halozyme”, “Parent”, “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Antares Pharma, Inc., a Delaware corporation (the “Seller” or “Antares”), and Atlas Merger Sub, Inc. (“Merger Sub” or the “Acquirer”), a Delaware corporation and wholly owned …Antares Pharma, Inc. (Antares or 'the company') is a drug device company that develops and markets self-injection pharmaceutical products and technologies. The company develops these products with its partners and is designed to provide functional and commercial advantages, such as reduced side effects, improved safety and efficacy and …Jan 25, 2022 · Antares Pharma Inc. Serghei Lungu v. Antares Pharma Inc, No. 21-1624 (3d Cir. 2022) Annotate this Case. Download PDF. Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes. This site is protected by reCAPTCHA and the ...

Apr 26, 2022 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ...

Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. Pfizer will assume full cost and responsibility for all clinical development, manufacturing, …

About Antares Pharma . Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.Antares Pharma, Inc. v. Medac Pharma Inc., 771 F.3d 1354, 1362 (Fed. Cir. 2014). As a result, the Court has previously held that the satisfaction of the requirements under 35 U.S.C. §251 is analogous to the requirements under 35 U.S.C. §112(a).100 Princeton South, Suite 300 . Ewing, New Jersey 08628 (609) 359-3020 . Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 1Antares Pharma, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other. Jurisdiction of. Incorporation) 1-32302 (Commission File. Number) 41-1350192 (I.R.S. Employer. Identification No.) 250 Phillips Blvd., Suite 290, Ewing, NJ . 08618 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area …The Antares Pharma Inc PEG ratio, or Antares Pharma Inc (price / earnings to growth) ratio, is a measure that helps Antares Pharma Inc investors value the Antares Pharma Inc business by taking into consideration the Antares Pharma Inc stock market price, earnings, and future growth potential of Antares Pharma Inc as a business.Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of James E. Fickenscher to the position of Senior Vice President, Chief Financial Officer. Mr. Fickenscher has a diversified corporate background including more than 25 years of experience in the pharmaceutical industry. Most recently, Mr. Fickenscher served as …11. 9. 2022 ... Antares Pharma, Inc, a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products ...Oct 18, 2021 · Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to commercialize TLANDO in the United States. TLANDO is an oral testosterone product for testosterone replacement therapy ("TRT") in ... Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. Pfizer will assume full cost and responsibility for all clinical development, manufacturing, …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...Oct 18, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... Dec 15, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

EWING - Antares Pharma, Inc. (NASDAQ: ATRS) ('the Company'), a pharmaceutical technology company, today announced that it entered into an exclusive license agreement with Ferring Pharmaceuticals ('Ferring'), a research-driven, specialty biopharmaceutical group, for the marketed product NOCDURNA (desmopressin …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Instagram:https://instagram. free practice trading accountig mt5us 30 year treasury yieldbest bank in alaska Abstract. Medi-Ject Corporation (now Antares Pharma, Inc.) has been providing delivery devices for the needle-free administration of insulin for over 25 years. This study was one of the final steps in the development and premarket evaluation of Medi-Ject's newest needle-free system, the Medi-Jector Vision. This study was conducted to evaluate ... sandp 500 200 day moving average chartlowes board Jun 23, 2007 · Description. Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others. Device Type: Auto-Injector: Dosage Type: Fixed: Injection Volume: 0.2-1.0ml Injection Type: SC or IM: Primary Container: 1.0ml long prefilled syringe shopify stock target price Delaware . 1-32302 . 41-1350192 (State or other jurisdiction. of incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...Jan 11, 2022 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...